- Almac Group has announced an £11 million investment to expand its global analytical services.
- The investment will create over 100 new jobs across its laboratories in the UK, US, and Ireland.
Almac Group, a global contract development and manufacturing organisation (CDMO), has confirmed an £11 million investment aimed at expanding its analytical services capabilities. This initiative, announced today, will also lead to the creation of over 100 new jobs across its global operations.
Over the past 18 months, Almac Sciences and Almac Pharma Services have collaborated to enhance their existing analytical laboratories and technologies to meet rising global demand. The investment will focus on expanding laboratory space at the company’s headquarters in Craigavon, UK, as well as upgrading facilities across other sites, including Charnwood, Souderton, Athlone, and Dundalk.
Almac employs over 700 skilled analysts in regulatory-approved GMP laboratories. The company develops and validates a significant number of analytical methods each year, supporting drug substance and product analytics through all development phases. The recent investment will strengthen Almac’s existing capabilities in areas such as chromatography and spectroscopy.
Darren Thomas, Vice President of Analytical Operations at Almac Sciences, stated, “We have experienced a significant increase in demand for our dedicated analytical solutions and recognise the importance of continually investing… in our systems and facilities, but also in our people.” This sentiment is echoed by Trevor Clarke, Vice President of Analytical Operations at Almac Pharma Services, who highlighted the company’s commitment to delivering excellence and comprehensive analytical solutions.
Overview of outsourcing trends 
